C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$5.38 USD
+0.04 (0.75%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $5.23 -0.15 (-2.79%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth B Momentum C VGM
C4 Therapeutics, Inc. (CCCC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.00 | $39.00 | $7.00 | 180.90% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for C4 Therapeutics, Inc. comes to $15.00. The forecasts range from a low of $7.00 to a high of $39.00. The average price target represents an increase of 180.9% from the last closing price of $5.34.
Analyst Price Targets (8 )
Broker Rating
C4 Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.75 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, five are Strong Buy, representing 62.5% of all recommendations. A month ago, Strong Buy represented 62.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/16/2024 | Evercore Partners | Gavin Clark-Gartner | Strong Buy | Strong Buy |
9/3/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/11/2024 | Wells Fargo Securities | Derek C Archila | Hold | Hold |
8/6/2024 | BMO Capital Markets | Etzer Darout | Strong Buy | Strong Buy |
2/23/2024 | Brookline Capital Markets | Leah R Cann | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.75 |
ABR (Last week) | 1.75 |
# of Recs in ABR | 8 |
Average Target Price | $15.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 252 |
Current Quarter EPS Est: | -0.40 |
CCCC FAQs
C4 Therapeutics, Inc. (CCCC) currently has an average brokerage recommendation (ABR) of 1.75 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 8 brokerage firms.
The average price target for C4 Therapeutics, Inc. (CCCC) is $15.00. The current on short-term price targets is based on 4 reports.
The forecasts for C4 Therapeutics, Inc. (CCCC) range from a low of $7 to a high of $39. The average price target represents a increase of $178.81 from the last closing price of $5.38.
The current UPSIDE for C4 Therapeutics, Inc. (CCCC) is 178.81%
Based on short-term price targets offered by eight analysts, the average price target for C4 Therapeutics, Inc. comes to $15.00. The forecasts range from a low of $7.00 to a high of $39.00. The average price target represents an increase of 180.9% from the last closing price of $5.34.